Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 4
1979 5
1980 3
1981 3
1982 5
1983 7
1984 6
1985 10
1986 5
1987 12
1988 10
1989 12
1990 6
1991 8
1992 10
1993 6
1994 8
1995 7
1996 11
1997 1
1998 5
1999 8
2000 8
2001 5
2002 7
2003 11
2004 6
2005 11
2006 15
2007 10
2008 7
2009 5
2010 6
2011 4
2012 3
2013 1
2018 1
2020 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

250 results
Results by year
Filters applied: . Clear all
Page 1
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. Mössner E, et al. Among authors: poppema s. Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1. Blood. 2010. PMID: 20194898 Free PMC article.
Biology of Hodgkin's disease.
Poppema S, Kaleta J, Hepperle B, Visser L. Poppema S, et al. Ann Oncol. 1992 Sep;3 Suppl 4:5-8. doi: 10.1093/annonc/3.suppl_4.s5. Ann Oncol. 1992. PMID: 1333271 Review.
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX, Arip M, Yahaya AAA, Jazayeri SD, Poppema S, Poh CL. Lim HX, et al. Among authors: poppema s. Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024. Front Biosci (Landmark Ed). 2021. PMID: 34856768 Free article. Review.
Immunology of Hodgkin's disease.
Poppema S. Poppema S. Baillieres Clin Haematol. 1996 Sep;9(3):447-57. doi: 10.1016/s0950-3536(96)80020-5. Baillieres Clin Haematol. 1996. PMID: 8922239 Review.
Prognostic biomarkers in malignant lymphomas.
Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Gascoyne RD, et al. Among authors: poppema s. Leuk Lymphoma. 2010 Aug;51 Suppl 1:11-9. doi: 10.3109/10428194.2010.500046. Leuk Lymphoma. 2010. PMID: 20658955 Review.
Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma).
Rüdiger T, Jaffe ES, Delsol G, deWolf-Peeters C, Gascoyne RD, Georgii A, Harris NL, Kadin ME, MacLennan KA, Poppema S, Stein H, Weiss LE, Müller-Hermelink HK. Rüdiger T, et al. Among authors: poppema s. Ann Oncol. 1998;9 Suppl 5:S31-8. doi: 10.1093/annonc/9.suppl_5.s31. Ann Oncol. 1998. PMID: 9926235 Review.
Active specific immunotherapy against adenocarcinomas.
MacLean GD, Reddish MA, Bowen-Yacyshyn MB, Poppema S, Longenecker BM. MacLean GD, et al. Among authors: poppema s. Cancer Invest. 1994;12(1):46-56. doi: 10.3109/07357909409021392. Cancer Invest. 1994. PMID: 7506634 Review. No abstract available.
250 results